Healthcare
Live Price
Offline$4.73
+3.05% today
1Y Change
-65.44%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
RxSight, Inc. (RXST) is a Healthcare stock with a market cap of $300.00M and listed on NASDAQ. The stock last traded around $4.73 and down 65.4% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of -3.9%, EPS growth of -33.8%, a dividend yield of 0.0%. What stands out right now is revenue -3.9%, EPS -33.8%, free cash flow +13.6% with operating margin -35.8% and ROIC -16.8%. Valuation is more restrained than many high-expectation growth names at price/sales 2.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RXST price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RXST
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RXST Max Drawdown
-66.42%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RXST and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$22.6M
-53.9% YoY
FY Net Income
-$48.7M
+27.1% YoY
Free Cash Flow
-$46.6M
+23.8% YoY
Revenue Growth
-3.9%
EPS Growth
-33.8%
Gross Margin
76.6%
Net Margin
-29.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 134M | 140M | 89M | 49M | 23M |
| Gross Profit | 103M | 99M | 54M | 21M | 5M |
| Operating Income | -48M | -37M | -50M | -63M | -53M |
| EBITDA | -40M | -24M | -41M | -58M | -41M |
| Net Income | -39M | -27M | -49M | -67M | -49M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 20M | 17M | 10M | 12M | 24M |
| Total Assets | 312M | 319M | 183M | 150M | 193M |
| Total Liabilities | 36M | 37M | 22M | 60M | 54M |
| Shareholder Equity | 276M | 281M | 160M | 90M | 138M |
| Total Debt | 11M | 12M | 3M | 45M | 45M |
| Net Debt | -9M | -4M | -7M | 33M | 21M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
45M
+24.0% YoY
Capital Expenditures
2M
+18.9% YoY
Free Cash Flow
47M
+23.8% YoY
Key ratios
Gross Margin
76.6%
Operating Margin
-35.8%
Net Margin
-29.0%
ROE
-14.0%
Debt / Equity
0.04x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.